HK Stock Market Move | PEGBIO CO-B (02565) rose more than 10% in late trading; Vipenatide is expected to be included in medical insurance, and the company's financing safeguards the next round of product R&D.

PEGBIO CO-B (02565) rose more than 10% in late trading. As of press time, it was up 8.16% at HK$3.645, with a turnover of HK$116 million. On the news front, PEGBIO disclosed that it plans to place 26.813 million new H shares, raising net proceeds of approximately HK$77.16 million. In addition, Vipenatide has entered the relevant procedures for the 2026 adjustment of the National Reimbursement Drug List (NRDL). As the announcement of the new round of the NRDL approaches, the product's medical insurance access progress has drawn market attention. If successfully included in the NRDL, it is expected to further enhance patient accessibility to the drug and create conditions for subsequent commercialization ramp-up. It is worth noting that projects such as PB-2312 and PB-2309 together form PEGBIO's next-generation R&D pipeline. The company plans to allocate approximately 60% of the net proceeds from this placement to these innovative pipelines, indicating that even after its existing products have entered commercialization, the company continues to invest resources in the next round of product competition.